# EDGAR Filing Document

**Accession Number:** 0001119774
**File Stem:** 0001178913-26-000968
**Filing Date:** 2026-3
**Character Count:** 5704
**Document Hash:** 3d6ef992aef2181f64d21367208df626
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-000968.hdr.sgml**: 20260415

**ACCESSION NUMBER**: 0001178913-26-000968

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Ferre Pierre
- **CENTRAL INDEX KEY:** 0001972518

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30902
- **FILM NUMBER:** 26764751

**MAIL ADDRESS:**
- **STREET 1:** 14 RUE DES ABEILLES
- **CITY:** TOULOUSE
- **STATE:** I0
- **ZIP:** 3100
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** COMPUGEN LTD
- **CENTRAL INDEX KEY:** 0001119774
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 26 HAROKMIM STREET
- **STREET 2:** BUILDING D
- **CITY:** HOLON
- **STATE:** L3
- **ZIP:** 5885849
- **BUSINESS PHONE:** 011-972-3-765-8585

**MAIL ADDRESS:**
- **STREET 1:** 26 HAROKMIM STREET
- **STREET 2:** BUILDING D
- **CITY:** HOLON
- **STATE:** L3
- **ZIP:** 5885849

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Ferre Pierre<br><sub>(Last) (First) (Middle)</sub><br>C/O COMPUGEN LTD.<br>26 HAROKMIM STREET<br><sub>(Street)</sub><br>HOLON,  5885849<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>COMPUGEN LTD [ CGEN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Operating Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Share Option (right to buy) | <sup>(1)</sup> | 2031-07-27 | Ordinary Shares | 100000 | $6.45 | D |  |
| Share Option (right to buy) | <sup>(2)</sup> | 2032-03-24 | Ordinary Shares | 65000 | $5 | D |  |
| Share Option (right to buy) | <sup>(3)</sup> | 2032-11-09 | Ordinary Shares | 30000 | $3 | D |  |
| Share Option (right to buy) | <sup>(4)</sup> | 2033-08-03 | Ordinary Shares | 65000 | $3 | D |  |
| Share Option (right to buy) | <sup>(5)</sup> | 2034-07-31 | Ordinary Shares | 70000 | $4 | D |  |
| Share Option (right to buy) | <sup>(6)</sup> | 2035-08-05 | Ordinary Shares | 70000 | $4 | D |  |

---

### Footnotes:

(1) Fully vested.

(2) This option vested 25% on March 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

(3) This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

(4) This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

(5) This option vested 25% on September 30, 2025 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

(6) This option vests 25% on September 30, 2026 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

**Signature:** /s/ Pierre Ferre  
**Date:** 2026-03-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**